Journal of cancer immunology最新文献_第3页

Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer? Butein能成为治疗晚期转移性甲状腺癌的候选药物吗?

Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.064

Devavrat Tripathi, S. Kulkarni

{"title":"Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?","authors":"Devavrat Tripathi, S. Kulkarni","doi":"10.33696/cancerimmunol.4.064","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.064","url":null,"abstract":"The incidence and prevalence of papillary thyroid cancer (PTC) are increasing worldwide and it is the 5th most common endocrine cancer in females [1]. In addition to this, the frequency of resistance toward radio-iodine therapy is also increasing in PTC patients (Advanced metastatic thyroid cancer). External beam radiation therapy (EBRT) and chemotherapy are used for the treatment of such patients. EBRT and Chemotherapy are associated with serious side effects and toxicity. US-FDA has also approved two drugs (Sorafenib and Lenvatinib) for the treatment of advanced thyroid cancer patients. However, the efficacy of both drugs is limited in terms of overall survival and disease-free survival and associated with severe toxicities [2]. Hence, the treatment of patients with advanced metastatic thyroid cancer represents a major challenge for clinicians and oncologists. In such patients, tumor cells show invasion in local neck regions, lungs, and bones [3]. Metastasis is the most dangerous aspect of cancer and is responsible for 90% of deaths of cancer. Epithelial -mesenchymal transition (EMT) and cancer stem cells (CSC) are the driving forces of metastasis and therapeutic resistance [4]. Hence, this axis of EMT and CSCs is a major target from the new therapy point of view.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45853678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across Races: A Review Tyrer-Cuzick 8乳腺癌风险模型跨种族的表现综述

Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.065

引用次数: 0

Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy 离合器控制:改变CAR-T细胞治疗的速度和方向

Journal of cancer immunology Pub Date : 2022-11-30 DOI: 10.33696/cancerimmunol.4.066

Alberto Nobili, A. Kobayashi, Patrick C. Gedeon, C. Novina

引用次数: 0

Journal of cancer immunology Pub Date : 2022-04-01 DOI: 10.33696/cancerimmunol.4.060

引用次数: 0

OGR1-a Novel Modulator Target of Tumor Immunotherapy 肿瘤免疫治疗的新调控靶点ogr1

Journal of cancer immunology Pub Date : 2022-04-01 DOI: 10.33696/cancerimmunol.4.062

引用次数: 0

Clinical, FDG-PET and Molecular Markers of Immune Checkpoint Inhibitor Response in Patients with Advanced Merkel Cell Carcinoma 晚期Merkel细胞癌患者免疫检查点抑制剂反应的临床、FDG-PET和分子标记

Journal of cancer immunology Pub Date : 2022-04-01 DOI: 10.33696/cancerimmunol.4.058

引用次数: 1

MEK Inhibition in KRAS Mutated NSCLC: Quo vadis? KRAS突变的NSCLC中MEK的抑制作用:是否有效?

Journal of cancer immunology Pub Date : 2022-04-01 DOI: 10.33696/cancerimmunol.4.059

引用次数: 0

Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies. 植物病毒纳米粒子 (PVNPs) 在抗癌免疫疗法中的新兴潜力。

Journal of cancer immunology Pub Date : 2022-01-01 DOI: 10.33696/cancerimmunol.4.061

Mehdi Shahgolzari, Steven Fiering

{"title":"Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies.","authors":"Mehdi Shahgolzari, Steven Fiering","doi":"10.33696/cancerimmunol.4.061","DOIUrl":"10.33696/cancerimmunol.4.061","url":null,"abstract":"Cancer immunotherapies using plant virus nanoparticles (PVNPs) have achieved considerable success in preclinical studies. PVNP based nanoplatforms can be endogenous immune adjuvants and act as nanocarriers that stabilize and deliver cancer antigens and exogenous immune adjuvants. Although they do not infect mammalian cells, PVNPs are viruses and they are variably recognized by pathogen pattern recognition receptors (PRR), activate innate immune cells including antigen-presenting cells (APCs), and increase the expression of costimulatory molecules. Novel immunotherapy strategies use them as in situ vaccines (ISV) that can effectively inhibit tumor growth after intratumoral administration and generate expanded systemic antitumor immunity. PVNPs combined with other tumor immunotherapeutic options and other modalities of oncotherapy can improve both local and systemic anti-tumor immune responses. While not yet in clinical trials in humans, there is accelerating interest and research of the potential of PVNPs for ISV immune therapy for cancer. Thus, antitumor efficacy of PVNPs by themselves, or loaded with soluble toll-like receptor (TLR) agonists and/or cancer antigens, will likely enter human trials over the next few years and potentially contribute to next-generation antitumor immune-based therapies.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"4 1","pages":"22-29"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10117317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy. 离合器控制:改变CAR-T细胞治疗的速度和方向。

Journal of cancer immunology Pub Date : 2022-01-01

Alberto Nobili, Aya Kobayashi, Patrick C Gedeon, Carl D Novina

引用次数: 0

Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ?50% Non-Small Cell Lung Cancer Treatment Pembrolizumab对一线晚期PD-L1疗效的生物标志物？50%非小细胞肺癌癌症治疗

Journal of cancer immunology Pub Date : 2021-12-31 DOI: 10.33696/cancerimmunol.3.056

L. Cabezón-Gutiérrez, S. Custodio-Cabello, Magda Palka-Kotlowska, Sílvia, María Sanchez-Luis, P. Khosravi-Shahi

引用次数: 0